To compensate for this limitation, we conducted the Submap analyses in HCC cohorts and PD‐L1 IHC assays in the TMA cohort, which could confirmed the correlation between GBPs and the response to anti‐PD1 treatment. The gene discussed is CD274; the disease is hepatocellular carcinoma.